300+ investors in your industry, stage, and region Get
Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
South Korea
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Andorra
Colombia
Sudan
Costa Rica
China
Armenia
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
South Africa
Canada
Ireland
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Windham Venture Partners, VC Fund

Windham Venture Partners

VC Fund

New York, United States

Windham Venture Partners is a VC fund in New York focused on Health Care and Medical. Founded in 2006, Windham is a New York City based venture capital firm focused on healthcare, with a particular emphasis on medical technology (devices and diagnostics) and digital health (the intersection of biology, genomics, and information technology). Windham seeks to invest in and partner with companies that are commercializinggame-changing technologies to serve unmet needs in order to improve the lives of large numbers of patients and yield robust returns for its investors. For more information visit: www.windhamvp.com

Total investments:
66
Last investment:
Lead investor:
12%
Fund size:
$31M
Last fund:

Last updated:

Industries Windham Venture Partners invests in

Health CareMedicalMedical DeviceBiotechnologyHealth Diagnostics

Stages Windham Venture Partners invests in

Series BSeries CSeries AVenture - Series UnknownSeries D

Countries Windham Venture Partners invests in

United StatesIsrael

Round sizes

Series A $4.3M–$101MSeries B $7M–$75MSeries C $12M–$73M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$4.3M–$101M
Series B
$7M–$75M
Series C
$12M–$73M

Investment Focus

Industry

  • Health Care 29 (44%)
  • Medical 13 (20%)
  • Medical Device 13 (20%)
  • Biotechnology 11 (17%)
  • Health Diagnostics 8 (12%)
See all 52 industries →

Stage

  • Series B 18 (27%)
  • Series C 12 (18%)
  • Series A 9 (14%)
  • Venture - Series Unknown 9 (14%)
  • Series D 6 (9%)
See all 11 stages →

Country

  • United States 34 (52%)
  • Israel 2 (3%)

Team

NameTitleInvestmentsLinksEmail
Adam Fine
Adam Fine Co-Founder, General Partner & CEO
Co-Founder, General Partner & CEO Total investments: 8
Find email
Lorne Taichman
Lorne Taichman Director of Science & Technology
Director of Science & Technology Total investments: 0
Find email
Roger Fine
Roger Fine Co-Founder & Chairman; Chairman of the Robert Wood Johnson Foundation
Co-Founder & Chairman; Chairman of the Robert Wood Johnson Foundation Total investments: 0
Find email
David J. Kereiakes
David J. Kereiakes Managing Partner
Managing Partner Total investments: 3
Find email
Joe Proto
Joe Proto Venture Partner
Venture Partner Total investments: 5
Find email

Investments

CompanyDescriptionRoundLinks
Fore Biotherapeutics Fore Biotherapeutics
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. $67.4M / Series D / Jul 07, 2026
PainTEQ PainTEQ
PainTEQ provides solutions and services to the interventional pain management community. Venture - Series Unknown / Aug 27, 2025
TailorMed TailorMed
TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data setto create actionable insights. $27.5M / Series B / Nov 21, 2024
TailorMed TailorMed
TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data setto create actionable insights. $27.5M / Series B / Nov 21, 2024
NeuSpera Medical NeuSpera Medical
NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeperand more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain $23M / Series D / Jul 15, 2024
Alto Neuroscience Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. $45M / Series C / Nov 21, 2023
Revelle Aesthetics Revelle Aesthetics
Revelle Aesthetics features a team of the brightest and most passionate minds in the medical device and aesthetics industries. It was born from ExploraMed, a leading medtech incubator. $30M / Venture - Series Unknown / Jun 01, 2023
Clever Care Health Plan Inc. Clever Care Health Plan Inc.
Clever Care Health Plan is a healthcare company that offers medicare advantage health plans to its members. Clever Care Health Plan offers culturally sensitive health care solutions that provide members better access to the services they need, in the language they understand.The company was founded in 2019 and headquartered in Westminster,California with a second office in Arcadia, CA. $42M / Series C / Mar 15, 2023
Alto Neuroscience Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. $35M / Series B / Oct 25, 2022
SubjectWell SubjectWell
SubjectWell is the risk-free clinical trials marketplace for patient recruitment $35M / Series B / Oct 18, 2022
See all 66 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
South Korea
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Andorra
Colombia
Sudan
Costa Rica
China
Armenia
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
South Africa
Canada
Ireland
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Windham Venture Partners invest in?

Windham Venture Partners invests primarily in Health Care, Medical and Medical Device startups, most often at Series B and Series C stage. Most of the 66 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Windham Venture Partners's check size?

Windham Venture Partners typically joins rounds of $4.3M–$101M at Series A, $7M–$75M at Series B and $12M–$73M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Windham Venture Partners participates in.

How do I contact Windham Venture Partners?

Public channels for Windham Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Windham Venture Partners?

The team at Windham Venture Partners includes Adam Fine (Co-Founder, General Partner & CEO), Lorne Taichman (Director of Science & Technology) and Roger Fine (Co-Founder & Chairman; Chairman of the Robert Wood Johnson Foundation). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Windham Venture Partners Windham Venture Partners Find emails